Kala Bio Stock Slides -42% With A 8-Day Losing Spree
Kala Bio (KALA) stock hit day 8 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -42% return. The company has lost about $7.9 Mil in value over the last 8 days, with its current market capitalization at about $11 Mil. The stock remains 92.0% below its value at the end of 2024. This compares with year-to-date returns of 15.6% for the S&P 500.
Kala Bio’s recent streak saw shares tumble following the unexpected dismissal of its auditor and a capital injection coupled with a new CEO, signaling financial distress post-failed eye drug trials. This confluence of events fueled investor uncertainty.
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact.For quick background, KALA focuses on developing and commercializing therapies using proprietary mucus penetrating particles technology for ocular conditions, including treatments for dry eye disease and corneal epithelial defects.
Comparing KALA Stock Returns With The S&P 500
- CVS Health Stock Shares $24 Bil Success With Investors
- PayPal Stock Pays Out $25 Bil – Investors Take Note
- Intuit Stock Testing Price Floor – Buy Now?
- Netflix Stock Hits Key Support – Buying Opportunity?
- Veeva Systems Stock Delivers Strong Cash Yield – Upside Ahead?
- Pay Less, Gain More: EQT Tops EOG Resources Stock
The following table summarizes the return for KALA stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | KALA | S&P 500 |
|---|---|---|
| 1D | -8.3% | -0.2% |
| 8D (Current Streak) | -42.4% | -0.8% |
| 1M (21D) | -21.3% | 1.0% |
| 3M (63D) | -96.8% | 3.0% |
| YTD 2025 | -92.0% | 15.6% |
| 2024 | -0.9% | 23.3% |
| 2023 | -81.7% | 24.2% |
| 2022 | -36.9% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 24 S&P constituents with 3 days or more of consecutive gains and 91 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 6 | 66 |
| 4D | 3 | 19 |
| 5D | 5 | 2 |
| 6D | 6 | 2 |
| 7D or more | 4 | 2 |
| Total >=3 D | 24 | 91 |
Key Financials for Kala Bio (KALA)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-34.3 Mil | $-34.2 Mil |
| Net Income | $-42.2 Mil | $-38.5 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-10.3 Mil | $-10.2 Mil |
| Net Income | $-11.2 Mil | $-7.6 Mil |
The losing streak KALA stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.